<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Barreto, Andrew D.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Combination Full-Dose IV-tPA + Argatroban is Safe and May Result in Higher Rates of Recanalization</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2011-03-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">17-18</style></pages><abstract><style  face="normal" font="default" size="100%">Argatroban is a direct thrombin inhibitor that safely augments the benefit of tPA in animal stroke models; however, human data are limited. The Argatroban tPA Stroke Study [ARTSS; NCT00268762] is a multicenter, Phase II, prospective, open-label, safety and activity study of argatroban and tPA in patients with ischemic stroke.</style></abstract><number><style face="normal" font="default" size="100%">1</style></number><volume><style face="normal" font="default" size="100%">11</style></volume></record></records></xml>